Futura Medical plc (FUM) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Futura Medical PLC 4-year results investor presentation. Throughout this recorded presentation, investors will be in listen-only mode. Questions are encouraged and they can be submitted at any time using the Q&A tab situated on the right-hand corner of your screen. Simply tap in your questions and press send. The company may not be in a position to answer every question or issue during the meeting itself. However, the company can review all questions submitted today and publish responses where it is appropriate to do so. Before we begin, I would like to submit the following poll, and I would now like to hand you over to CEO James Bader. Good morning to you. Good morning. My name is James Bader, and I am the CEO of Futura Medical, and I'm joined for today's presentation of the 23-year-old results by Angela Hillgrist, who is the Finance Director and Chief Operating Officer of Futura. Futura specialises in the development and commercialisation of innovative and proprietary sexual health products. Our lead product being Evoxon, a clinically proven breakthrough treatment for erectile dysfunction. We also describe ourselves as experts in research, development, and commercialization of topical liver cell formulations. I appreciate that for those longer-term shareholders, this is a change from a future of previous focus. Following the success of Oroxone, this is a deliberate change in strategy to concentrate our efforts and resource exclusively within the area of over-the-counter sexual health treatments. Erectile dysfunction, or ED, is a large underserved market with only a limited number of treatment options. Furthermore, there has not really been any new innovation in the treatment of erectile dysfunction in the past 20 years. Nothing reall...